(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary - Highlights from ESMO 2025 and the first International Cancer of Unknown Primary Meeting [0.03%]
未知的希望和机会：ESMO 2025 和首次国际原发不明癌症会议亮点回顾
Maximilian Haas,Louisa Hempel,Alwin Krämer et al.
Maximilian Haas et al.
Cancer of unknown primary (CUP) accounts for 1-3% of newly diagnosed cancers. For decades, management has relied on empirical platinum-based chemotherapy, which offers a poor prognosis with a median overall survival typically below one year...
What is new in the German S3 guideline on gastric cancer: diagnosis, staging and treatment [0.03%]
德国胃癌S3指南更新要点——诊断、分期和治疗
Markus Moehler,Yvonne Huber,Jan Bornschein et al.
Markus Moehler et al.
Background: Carcinomas of the stomach and esophagogastric junction (EGJ) are the fifth leading cause of cancer-related deaths worldwide. In Germany, gastric cancer ranks tenth in incidence across both sexes. This summary ...
Moving tumor-agnostic therapy to the big stage - translational and molecular oncology highlights from the ESMO Congress 2025 [0.03%]
迈向大舞台的肿瘤不可知疗法——ESMO 2025年会上关于转化和分子肿瘤学的亮点
Elisabeth Tregel,Damian T Rieke,Annalen Bleckmann et al.
Elisabeth Tregel et al.
Apatinib mesylate in the treatment of advanced triple-negative breast cancer [0.03%]
阿帕替尼治疗晚期三阴性乳腺癌的研究
Xijia Huang,Chao Chen,Hao Zeng et al.
Xijia Huang et al.
Background: The effectiveness of conventional chemotherapy in treating metastatic triple-negative breast cancer (TNBC) is unsatisfactory. Apatinib, a small-molecule tyrosine kinase vascular inhibitor (TKI), is a multi-tar...
Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapies [0.03%]
非霍奇金淋巴瘤患者开始使用抗CD20抗体类药物治疗的感染易感性和继发性免疫缺陷
Rudolf Weide,Johannes Mohm,Michael Gärtner et al.
Rudolf Weide et al.
Background: Only limited data exist about immune status, secondary immunodeficiencies and vulnerability to infections in correlation to anti-CD20 antibody containing therapies (CD20CT) in non-Hodgkin's lymphoma (NHL) pati...
KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions [0.03%]
非小细胞肺癌伴中枢神经系统受累的KRAS抑制：现有证据和未来方向
Rafael Alvim Pereira,Christian Oliveira,Milena Tumelero et al.
Rafael Alvim Pereira et al.
Background: KRAS mutations, particularly G12C, frequently cause non-small cell lung cancer (NSCLC). Due to the protective nature of the blood-brain barrier and the paucity of clinical data specifically about CNS involveme...
Quality of life and patient-reported outcomes (PRO): Highlights from the European Society for Medical Oncology Annual Meeting (ESMO) Congress 2025 [0.03%]
2025年欧洲医学肿瘤学会年会(ESMO)关于患者报告结果(PRO)和生活质量的亮点
Anna Franziska Hamm,Thomas Michaeli
Anna Franziska Hamm
Retraction Statement [0.03%]
撤回声明
The authors' accepted manuscript "TACE Combined with Hepatic Arterial Infusion of Nivolumab for Inhibiting Tumor Angiogenesis in Hepatocellular Carcinoma" [Oncol Res Treat. 2025; https://doi.org/10.1159/000549516] by Sujing Zhang, Zheng Zhe...
Axel Muendlein,Eva Maria Brandtner,Christine Heinzle et al.
Axel Muendlein et al.
Background & objective: Leucine-rich α-2 glycoprotein 1 (LRG1) is a multifunctional pro-inflammatory signaling molecule that has been proposed as a promising biomarker and potential therapeutic target across various type...